ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0309

Characteristics and Factors Associated with Treatment Response Among Patients with Eosinophilic Fasciitis: A Systematic Review and Meta-analysis
Abstract Number: 1340

Characteristics and Long-term Outcomes of Patients with Rheumatoid Arthritis and Concurrent Calcium Pyrophosphate Deposition Disease
Abstract Number: 1546

Characteristics and Treatment Patterns of Patients with Lupus Nephritis: A Retrospective Claims Database Study in the USA
Abstract Number: 0755

Characteristics Associated with Long-Term Glucocorticoids Use in Patients with New Onset Polymyalgia Rheumatica
Abstract Number: 1609

Characteristics of a Cohort of Patients with Interstitial Lung Disease and ANCA Positivity in a University Hospital
Abstract Number: 0297

Characteristics of Adult-Onset Still’s Disease Skin Eruption in Individuals of Sub-Saharan Ancestry
Abstract Number: 0077

Characteristics of Axial Spondyloarthritis in Patients with Onset Chronic Low Back Pain After Age 45
Abstract Number: 0573

Characteristics of Difficult-to-Treat Ankylosing Spondylitis- Results from Real-World Data
Abstract Number: 0211

Characteristics of Hospitalizations and Outpatient Follow-up for Patients with SLE at an Academic Hospital Setting in Austin, Texas
Abstract Number: 1163

Characteristics of Interstitial Lung Disease Progressors in an Antisynthetase Autoantibody-Positive Population
Abstract Number: 0209

Characteristics of Ordering Providers and Patients with Positive Antinuclear Antibodies: A Pragmatic, Risk Model Study
Abstract Number: 0344

Characteristics of Patients with Antisynthetase Antibodies
Abstract Number: 2334

Characteristics of Patients with Psoriatic Arthritis Presenting with Axial Involvement: Results of a Prospective International Multicenter Study (AXIS)
Abstract Number: 2652

Characteristics of Relapse and Therapeutic Management in Giant Cell Arteritis in Modern Era, NEWTON Study
Abstract Number: 1605

Characteristics of Relapses in Patients with Eosinophilic Granulomatosis with Polyangiitis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].